Abraxis signs agreement with AstraZeneca to reacquire US rights to Abraxane
Abraxis has developed an extensive clinical program that the company believes will form the basis for new indications for Abraxane as well as other product candidates for which
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.